PLoS ONE
(Jan 2019)
Correction: Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study.
Pirow Bekker,
Daniel Dairaghi,
Lisa Seitz,
Manmohan Leleti,
Yu Wang,
Linda Ertl,
Trageen Baumgart,
Sarah Shugarts,
Lisa Lohr,
Ton Dang,
Shichang Miao,
Yibin Zeng,
Pingchen Fan,
Penglie Zhang,
Daniel Johnson,
Jay Powers,
Juan Jaen,
Israel Charo,
Thomas J Schall
Affiliations
Pirow Bekker
Daniel Dairaghi
Lisa Seitz
Manmohan Leleti
Yu Wang
Linda Ertl
Trageen Baumgart
Sarah Shugarts
Lisa Lohr
Ton Dang
Shichang Miao
Yibin Zeng
Pingchen Fan
Penglie Zhang
Daniel Johnson
Jay Powers
Juan Jaen
Israel Charo
Thomas J Schall
DOI
https://doi.org/10.1371/journal.pone.0210593
Journal volume & issue
Vol. 14,
no. 1
p.
e0210593
Abstract
Read online
[This corrects the article DOI: 10.1371/journal.pone.0164646.].
WeChat QR code
Close